Human Fibroblast Reprogramming to Naïve Induced Pluripotent Stem Cells in Microfluidics
Induced pluripotent stem cells (iPSCs) are generated by expression of transcription factors OCT4, SOX2, KLF4 and cMYC (OSKM) in somatic cells. In contrast to murine naïve iPSCs, conventional human iPSCs are in a more developmentally advanced state called primed pluripotency. Here we report a detailed protocol for the generation of human naïve iPSCs (niPSCs) from less than 1000 primary human somatic cells without stable genetic manipulation by delivery of modified messenger RNAs with microfluidics. Expression of OSKM in combination with NANOG for 12 days generates niPSCs that are free of transgenes, karyotypically normal, and display transcriptional, epigenetic and metabolic features indicative of the naïve state. Specifically, we describe the production of microfluidics chips, the reprogramming of somatic cells into niPSCs and their expansion out of the microfluidics chips. Our microfluidics approach will allow robust and cost-effective production of patient-specific niPSCs for regenerative medicine applications, including disease modelling and drug screening.
Figure 1
Figure 2
Posted 10 Jan, 2019
Human Fibroblast Reprogramming to Naïve Induced Pluripotent Stem Cells in Microfluidics
Posted 10 Jan, 2019
Induced pluripotent stem cells (iPSCs) are generated by expression of transcription factors OCT4, SOX2, KLF4 and cMYC (OSKM) in somatic cells. In contrast to murine naïve iPSCs, conventional human iPSCs are in a more developmentally advanced state called primed pluripotency. Here we report a detailed protocol for the generation of human naïve iPSCs (niPSCs) from less than 1000 primary human somatic cells without stable genetic manipulation by delivery of modified messenger RNAs with microfluidics. Expression of OSKM in combination with NANOG for 12 days generates niPSCs that are free of transgenes, karyotypically normal, and display transcriptional, epigenetic and metabolic features indicative of the naïve state. Specifically, we describe the production of microfluidics chips, the reprogramming of somatic cells into niPSCs and their expansion out of the microfluidics chips. Our microfluidics approach will allow robust and cost-effective production of patient-specific niPSCs for regenerative medicine applications, including disease modelling and drug screening.
Figure 1
Figure 2